- Home
- SMHI vs TNXP Comparison
SMHI vs TNXP Comparison
Compare SMHI & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMHI
- TNXP
- Stock Information
- Founded
- SMHI 1989
- TNXP 2007
- Country
- SMHI United States
- TNXP United States
- Employees
- SMHI N/A
- TNXP N/A
- Industry
- SMHI Marine Transportation
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- SMHI Consumer Discretionary
- TNXP Health Care
- Exchange
- SMHI Nasdaq
- TNXP Nasdaq
- Market Cap
- SMHI 142.2M
- TNXP 118.2M
- IPO Year
- SMHI N/A
- TNXP N/A
- Fundamental
- Price
- SMHI $4.97
- TNXP $18.83
- Analyst Decision
- SMHI
- TNXP Strong Buy
- Analyst Count
- SMHI 0
- TNXP 2
- Target Price
- SMHI N/A
- TNXP $585.00
- AVG Volume (30 Days)
- SMHI 124.5K
- TNXP 577.6K
- Earning Date
- SMHI 04-30-2025
- TNXP 05-20-2025
- Dividend Yield
- SMHI N/A
- TNXP N/A
- EPS Growth
- SMHI N/A
- TNXP N/A
- EPS
- SMHI N/A
- TNXP N/A
- Revenue
- SMHI $264,089,999.00
- TNXP $10,094,000.00
- Revenue This Year
- SMHI $8.07
- TNXP $12.17
- Revenue Next Year
- SMHI $7.29
- TNXP $789.15
- P/E Ratio
- SMHI N/A
- TNXP N/A
- Revenue Growth
- SMHI N/A
- TNXP 29.94
- 52 Week Low
- SMHI $3.63
- TNXP $6.76
- 52 Week High
- SMHI $15.36
- TNXP $672.00
- Technical
- Relative Strength Index (RSI)
- SMHI 52.97
- TNXP 53.35
- Support Level
- SMHI $4.32
- TNXP $18.55
- Resistance Level
- SMHI $4.99
- TNXP $21.99
- Average True Range (ATR)
- SMHI 0.37
- TNXP 1.53
- MACD
- SMHI 0.04
- TNXP 0.22
- Stochastic Oscillator
- SMHI 61.50
- TNXP 58.64
About SMHI SEACOR Marine Holdings Inc.
Seacor Marine Holdings Inc provides marine and support transportation services to offshore energy facilities globally. The company operates and manages a diverse fleet of offshore support vessels that deliver cargo and personnel to offshore installations, including wind farms, handle anchors, and mooring equipment for offshore rigs and platforms. Its geographical segment includes the United States (Gulf of Mexico), Africa and Europe, Middle East and Asia, and Latin America.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.